Schering NDAs Not Subject To Extra Scrutiny Under FDA Consent Decree
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's pending supplemental NDAs to switch Claritin (loratadine) OTC appear to be unaffected by the company's GMP consent decree with FDA